secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001193125-24-058513
Event type: litigation
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio discloses supplemental proxy details to resolve merger-related shareholder lawsuits
--------------------------------------------------------------------------------

- Two federal lawsuits filed in CA and DE allege proxy omissions on LENZ financials, advisor conflicts; 12 additional demand letters received.
- Company voluntarily adds disclosures including Transaction Committee member compensation ($0 extra) and liquidation value of $2.86/sh in Feb 2024.
- Liquidation analysis per share in March 2027: $0.10 low case, $0.19 high case based on $5.6M-$11.1M net cash.
- Leerink DCF analysis yielded implied exchange ratio range of 2.8075-3.2957, valuing LENZ equity at $460M-$540M.
- Graphite denies allegations, states proxy complies with law; no executive officers expected to serve in combined company post-merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000119312524058513/0001193125-24-058513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000119312524058513/d772578d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-058513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer